Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

In previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At the 4-year follow-up, we report...

Descripción completa

Detalles Bibliográficos
Autores principales: Kater, Arnon P., Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D’Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R., Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, Seymour, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768340/
https://www.ncbi.nlm.nih.gov/pubmed/32986498
http://dx.doi.org/10.1200/JCO.20.00948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768340/
https://www.ncbi.nlm.nih.gov/pubmed/32986498
http://dx.doi.org/10.1200/JCO.20.00948

Ejemplares similares